Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367598 | 0.94 | MC4R (0.54) | MC4RKCNH2KDM4E | |
| Formic Acid SCHEMBL4906212 | 0.87 | MC4R (0.48) | MC4RKCNH2KDM4EALDH1A1MEN1 | |
| SCHEMBL4064122 | 0.84 | MC4R (0.56) | MC4RKCNH2KMT2A | |
| SCHEMBL4364676 | 0.83 | MC4R (0.65) | MC4RKCNH2 | |
| SCHEMBL4154587 | 0.82 | MC4R (0.52) | MC4RKCNH2KMT2ARUVBL1 | |
| Hydrochloric Acid SCHEMBL4914066 | 0.82 | MC4R (0.51) | MC4RKCNH2KMT2ARUVBL1 | |
| SCHEMBL4167272 | 0.81 | MC4R (0.55) | MC4RKCNH2KDM4EALDH1A1MEN1 | |
| SCHEMBL4147932 | 0.80 | MC4R (0.53) | MC4RKCNH2KDM4EMEN1KMT2A | |
| SCHEMBL4362042 | 0.79 | MC4R (0.52) | MC4RKCNH2KDM4EKMT2ARUVBL1 | |
| Formic Acid SCHEMBL4902744 | 0.78 | RUVBL1 (0.40) | MC4RKCNH2RUVBL1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | MC4R 1/4885KCNH2 3035/4885KDM4E 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.